drugset
drugset / Trial / NCT01719744

Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma

NCT01719744 ↗

Phase 2 Completed 25 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.

Timeline

Start
2013-01
Primary completion
2015-12
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ENMD-2076 Small molecule 275 mg Oral

Indications

metastatic malignant neoplasm soft tissue sarcoma